Show simple item record

dc.contributor.authorTheiss-Nyland, K.
dc.contributor.authorShakya, M.
dc.contributor.authorColin-Jones, R.
dc.date.accessioned2019-03-29T14:47:36Z
dc.date.available2019-03-29T14:47:36Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85062607027&doi=10.1093%2fcid%2fciy1106&partnerID=40&md5=910bfcf507abab1c609945801b934878
dc.identifier.urihttp://hdl.handle.net/10713/8686
dc.description.abstractBACKGROUND: Enteric fever is estimated to affect 11-20 million people worldwide each year. Morbidity and mortality from enteric fever primarily occur in lower-income countries, with children under 5 years of age experiencing a significant portion of the burden. Over the last few decades, the control of enteric fever has focused primarily on improved water and sanitation, with the available vaccines unsuitable for children and primarily used by travelers. A new typhoid conjugate vaccine (Vi-TCV), prequalified by the World Health Organization (WHO) and highly immunogenic in children under 5, has the potential to reduce the typhoid burden in endemic countries. METHODS: This study is a double-blinded, randomized, controlled trial with a 2-year follow-up to assess the protective impact of the Vi-TCV vaccine, compared with a control vaccine, in children from 9 months to 16 years of age. The primary outcome of interest is the reduction in the number of culture-confirmed typhoid cases attributable to Vi-TCV. Approximately 20 000 children living in the Lalitpur district, within the Kathmandu valley, will be enrolled in the study and followed to measure both safety and efficacy data, which will include adverse events, hospitalizations, antibiotic use, and fever frequency. RESULTS: Both the intervention and control vaccines are WHO prequalified vaccines, which provide a health benefit to all participants. Children have been chosen to participate because they bear a substantial burden of both typhoid morbidity and mortality in this population. The results of this study will be disseminated through a series of published articles. The findings will also be made available to the participants and the broader community, as well as local stakeholders, within Nepal. CONCLUSIONS: This is the first large-scale, individually randomized, controlled trial of Vi-TCV in children in an endemic setting, and will provide new data on Vi-TCV field efficacy. With Vi-TCV introduction being considered in high-burden countries, this study will support important policy decisions. CLINICAL TRIALS REGISTRATION: The trial is registered on the ISRCTN registry (for details, see https://doi.org/10.1186/ISRCTN43385161; registry number: ISRCTN 43385161). Copyright The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.en_US
dc.description.urihttps://dx.doi.org/10.1093/cid/ciy1106en_US
dc.language.isoen_USen_US
dc.publisherOxford Academicen_US
dc.relation.ispartofClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.subjectNepalen_US
dc.subjectprotocolen_US
dc.subjectrandomized control trialen_US
dc.subjecttyphoid vaccineen_US
dc.titleAssessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trialen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/cid/ciy1106
dc.identifier.pmid30845329


This item appears in the following Collection(s)

Show simple item record